Background The conventional antiviral treatment of chronic hepatitis related to hepatitis C virus (HCV) often leads to anemia. In this case, it is necessary to reduce ribavirin dose or stop treatment, thus reducing the rate of sustained virological response. Aim We investigated whether epoetin alpha administration improves treatment adherence and leads to higher percentage of response at the end of therapy and sustained virological response. Methods Two hundred and fourteen individuals with genotype 1b HCV-related chronic hepatitis underwent treatment with pegylated (peg)-interferon alpha-2A 180 μg once weekly and ribavirin 1,000-1,200 mg/day; 174 were responders.
Introduction
Hepatitis C virus (HCV) is a significant public health problem. As a hepatotropic virus, it could lead to chronic hepatitis (CH), cirrhosis, and hepatocellular carcinoma [1] . It can also cause several extrahepatic diseases, such as mixed cryoglobulinemia and lymphoma, on account of its lymphotropic pattern" [2, 3] . According to current guidelines, the standard treatment of HCV-related CH is based on the combination of pegylated interferon (peg-IFN) plus ribavirin (RBV) [4] [5] [6] [7] [8] . Such combination therapy may induce a normalization of transaminase levels, a sustained virological response (SVR), and histological hepatic improvement in about 65% of individuals infected with HCV genotype 1 and in about 80% of those infected with genotype 2 or 3 HCV [1, 9, 10] .
Beyond well-known predictive factors for an optimal therapeutic response (age <45 years, duration of disease <5 years, low levels of HCV RNA, genotype 2 or 3 HCV infection, lack of fibrosis, and intrahepatic iron upon hepatic biopsy), the adherence to standard peg-IFN and RBV therapy is necessary because it is associated with higher rates of therapeutic success [11, 12] . However, several factors contribute to imperfect adherence to therapy or, in some cases, to its interruption: therapy-induced reduction in hemoglobin (Hb) levels is the most important cause of dropout during treatment with peg-IFN and RBV [13] [14] [15] [16] [17] [18] [19] [20] . As a result, RBV dose reduction is required, with a corresponding decrease in the chance of an SVR [21] .
It is well known that RBV monotherapy lowers Hb levels by a hemolytic mechanism, whereas the inhibition of erythropoietin production during combination therapy with peg-IFN and RBV can induce anemia [22] [23] [24] . Therefore, epoetin alpha may become a pivotal therapy in patients who develop anemia during treatment with peg-IFN and RBV. In fact, patients can continue treatment with a standard optimal dose of peg-IFN and RBV and achieve positive therapeutic results with the persistence of high Hb levels. This aspect plays an especially important role in patients with advanced hepatic disease, because of the possibility of achieving stabilization of hepatic disease, in terms of clinical, biochemical and histological features, with a consequent improvement in quality of life (QOL) and an increased chance of survival [25] [26] [27] [28] [29] [30] [31] .
We investigated a group of patients with genotype 1b HCV-related CH treated with peg-IFN alpha-2A and RBV and consequently developed anemia. We aimed to establish whether treatment with epoetin alpha increased the number of patients who continued therapy with the standard dose of peg-IFN and RBV and increased the number of patients who achieve SVR.
Methods

Study design
The study was a longitudinal, prospective, randomized, open-label, controlled study performed in cooperation with three hepatology units. Epoetin alpha was administered according to Italian Agency of Drugs (AIFA, Agenzia Italiana del Farmaco) indications as expressed in Law n°6 48/96. All patients provided informed consent prior to inclusion in the study.
Patient selection
Criteria for admission to the therapy protocol with peg-IFN plus RBV were age 18 years or older, elevated serum alanine aminotransferase (ALT) levels over the prior 6 months, anti-HCV antibody positivity, detectable HCV RNA, HCV genotype 1b, liver histology of CH (Ishak score overall ≤13), baseline Hb >13 (men) and >12 (women), serum creatinine ≤1.5 mg/dl, Homeostatic Model Assessment Index (HOMA-IR) <2.5 [5, 6] . Exclusion criteria were HBV infection, HBV-HCV coinfection, HIV infection, HCV genotype other than 1b, overall Ishak score ≥13, decompensated cirrhosis, significant atherosclerotic heart disease (defined as instrumental and clinical features of coronary heart disease and chronic heart failure), starting Hb <13 (men) and <12 (women), alcohol or drug abuse, history of hematological disorders or neoplastic diseases, pregnancy, psychiatric disorders, autoimmune diseases, Wilson's disease, and hemochromatosis.
All patients underwent hepatitis B surface antigen (HBsAg), HCV RNA, and HCV genotype determination. Anti-HCV antibodies were determined by enzyme-linked immunosorbent assay (ELISA) (Ortho Diagnostic Systems, Raritan, NJ, USA) [32] . Pretreatment HCV RNA levels were detected by polymerase chain reaction (PCR) of HCV RNA 5' UTR using COBAS® AmpliPrep/COBAS® TaqMan® HCV Test (Roche Diagnostics Systems, Branchburg, NJ, USA; analytic sensitivity =50 IU/ml) [33] . HCV genotypes were determined by INNO-LiPA (Innogenetics) assay using Simmond's classification [34, 35] . Antinuclear (ANA), antimitochondrial (AMA), anti-smooth-muscle (SMA), antiliver/kidney microsome type 1 (LKM1) autoantibodies were measured using immunofluorescence assay (IFA) and semiquantitative ELISA immobilizing enzyme test [36] . Thyroid function was evaluated by levels of thyroid-stimulating hormone (TSH), free T3, and free T4 determined by immunoradiometric assay (IRMA); antibodies against thyroid peroxidase and thyroglobulin were measured by IFA [37] . Patients underwent ultrasoundassisted percutaneous biopsy obtained with Menghini modified needles (Automatic Aspiration Needle for Liver Biopsy, ACR 16G, 11 cm, manufactured by Sterylab Srl, Milan, Italy) within 6 months before the start of the study. Histological evaluation of the degree of necroinflammatory activity (grading) and fibrosis (staging) of hepatic tissue was carried out using the Ishak scoring system. Semiquantitative evaluation of the degree and distribution of hepatic iron storage was assessed according to the classification system of Deugnier et al. and intra hepatic iron was assessed using Perl's Prussian blue staining [38, 39] . Serum levels of iron, saturated transferrin, total transferrin (total iron-binding capacity, TIBC), unsaturated transferrin (unsaturated iron-binding capacity, UIBC), and ferritin were determined, and saturation of transferrin was calculated as serum level of iron/TIBC × 100. Genetic testing to identify hemochromatosis HFE gene mutations was performed to exclude individuals with hereditary hemochromatosis [40] . μg once weekly, plus oral WBR in two separate doses (total dose 1,200 mg daily for patients weighing >75 kg and 1,000 mg daily for those weighing <75 kg). Two weeks after the start of therapy and subsequently on a monthly basis, patients were evaluated clinically, and serum levels of transaminases, sodium, potassium, TSH, free T3, free T4, antibodies against thyroid peroxidase and thyroglobulin, glycemia, azotemia, creatininemia, International Normalized Ratio (INR) determination, hemachrome, and indexes of body iron were assessed.
In compliance with international guidelines and recommendations of the American Association for the Study of Liver Disease (AASLD) and the Italian Association for the Study of the Liver (AISF), HCV RNA levels were measured in all patients at weeks 12, 24, 48, and 72 [1, 6] . Patients with a HCV RNA reduction of at least 2 log 10 at week 12 in comparison with pretreatment HCV RNA values were classified as early virological responders (EVR) and continued therapy. Patients who did not reach this target were classified as nonresponders, and therapy was stopped. EVRs who showed a reduction of Hb serum levels >2 g/dl compared with Hb pretreatment value were 1:1 randomly distributed into two groups by computerbased randomization software. Participants in group 1 were admitted to continue peg-IFN alpha-2A and WBR dosage (1,000-1,200 mg/day) plus subcutaneous epoetin alpha, 10,000 IU twice weekly; participants in group 2 were admitted to continue peg-IFN alpha-2A with a weight-based reduction of RBV dose (800-1,000 mg/day). Administration of epoetin alpha in group 1 followed acquisition of patients' informed consent, as clearly indicated by Italian Law n°684/1996 concerning extension of the indicationsto-use of epoetins, which must be based on the most recent and proved evidence in the scientific literature. For all patients who underwent antiviral therapy, QOL was evaluated using the Linear Analogue Self-Assessment (LASA) scale by both activity and energy score at the beginning of the study and at weeks 4, 12, 24, 36, and 48 [31] . The primary efficacy endpoint was SVR defined as undetectable serum HCV RNA levels (<50 IU/ml) 24 weeks after the end of therapy (week 72).
Randomization and statistical analysis
The randomization process was performed through SAS® Software (Chicago, Il, USA). Results are presented as means ± standard deviation (SD), range, and frequencies. Fisher's exact test and Mann-Whitney U test for independent samples were applied. Two-tailed P values <0.01 were considered statistically significant. The impact of baseline factors and exposure to ribavirin were evaluated by multiple logistic regression (MLR) analyses. A predictive model was developed for primary endpoint (SVR). Baseline ALT Alanine Aminotransferase, AST aspartate aminotransferase, Hb hemoglobin, HCV hepatitis C virus, HBV hepatitis B virus, HIV human immunodeficiency virus, Plt platelets, INR International Normalized Ratio, LASA Linear Analog Self-Assessment scale a Values are expressed as the mean ± standard deviation (SD). Body-mass index is the weight in kilograms divided by the square of the height in meters. All liver specimens were assessed by a local pathologist for histology status and reviewed by one expert pathologist blinded to specimen group origin b LASA scale, with both activity and energy score, was performed to evaluate quality of life (QOL) at the beginning of the study and at weeks 4, 12, 24, 36, and 48 factors considered for inclusion in the models were age, body weight, body mass index (BMI), HOMA-IR, Hb, and HCV RNA level at week 0 and week 12 as continuous variables, with gender and histological stage as categorical variables. Drug exposure was converted to the percentage of optimal dose and was included in the models as a continuous variable.
Results
All patients were negative for ANA, AMA, SMA and LKM1 autoantibodies. Thyroid function, as evaluated by levels of TSH, free T3, and free T4, was also normal. Autoantibodies against thyroid peroxidase and thyroglobulin were absent at the beginning of therapy. However, in eight patients, they were positive during treatment and decreased progressively after the end of antiviral therapy, except in one patient who continued to have mild thyroiditis. Prior to treatment, all patients had a mean Hb level of 13.8±0.9 g/dl. Four weeks after the start of therapy, we noted a reduction in Hb and consequent asthenia, insomnia, and loss of concentration. At week 12, no significant statistical difference was found between the three groups concerning the following parameters: total bilirubin, platelets count, Hb, ferritin, and albumin serum levels. At week 12, 174/214 patients (81.3%) achieved an EVR, whereas 40/214 (18.7%) dropped out because they were nonresponders and stopped therapy. Forty of 174 EVR patients (23%) showed no decrease of Hb serum levels >2 g/dl during the study period and fully completed the treatment protocol (control group). Reduction of Hb levels >2 g/dl (mean value 11.4±1.3 g/dl) compared with pretreatment values was achieved in 134/174 (77%) EVR patients. They also had worsening treatment compliance, such that about 60% of responders would have preferred to stop therapy. They were randomly distributed into two groups: 67 in group 1 received subcutaneous epoetin alpha, 10,000 IU twice weekly, in addition to peg-IFN alpha-2A 180 μg/week + WBR 1,000-1,200 mg/day; 67 patients in group 2 received peg-IFN alpha-2A 180 μg/week and reduced doses of RBV (800-1,000 mg/day). Both study groups and the control group were followed up monthly during the 48 weeks of treatment up to 6 months after treatment interruption. In group 1, 42/67 patients (62.7%) showed undetectable HCV RNA serum levels at week 48 and were classified as end-of-treatment responders (ETR); 25/67 (37.3%) showed HCV RNA serum levels still detectable. In group 2, there were 35/67 (52.5%) ETRs; patients with detectable HCV RNA serum levels numbered 32/67 (47.8%).
Six months after the end of treatment (week 72), SVR was assessed. Forty of 67 patients in group 1 (59.7%) achieved an SVR; 2/67 (3%) had a relapse of disease during follow-up detected through HCV RNA assay and elevated transaminase levels. In group 2, 23/67 (34.4%) achieved SVR; 12/67 relapsed (17.9%). In the control group 26/40 (65%) were ETRs and 24/40 (60%) achieved SVR; 2/40 (5%) were relapsers (Fig. 1) .
During the course of treatment, no patient showed Hb serum levels <10 g/dl. However, in 19/67 (28.3%) EVR patients, therapy was suspended for 3 weeks because of worsening asthenia and QOL and incomplete adherence to therapy. The difference in SVR rate was statistically significant comparing group 2 with group 1 and the control group (p <0.01). Otherwise, no statistically significant difference was found comparing SVR rates between group 1 and the control group, and no difference was found in ETR rate between all groups (Table 3) . Patients in group 2 who received a reduced RBV dosage did not achieve an Hb increase and showed an SVR rate lower than that of patients in group 1, who maintained the standard dose of peg-IFN alpha-2A and RBV by the addition of epoetin alpha and showed a significant increase of Hb serum levels (Fig. 2) . Therefore, only in group 1 treated with epoetin alpha was the "80/80/80 rule" respected, i.e., administration of at least 80% of the dose of peg-IFN and RBV for at least 80% of the treatment time [42] .
Evaluation of QOL by the LASA scale showed that mean scores of patients treated with epoetin alpha (group 1) were significantly superior to those in group 2 concerning tolerability, adherence to treatment, few side effects, and improved QOL. In particular, good results in the changes in activity and energy score were observed in group 1 at 36 weeks (energy score change 18±17.3 and activity score change 20±18.5) compared with the results obtained in group 2 (energy score change 12.2±21.6 and activity score change 7±18.7) (P<0.05 for energy score change and P< 0.01 for activity score change). In the QOL assessment, rates of asthenia, loss of concentration, and insomnia were also evaluated, and a comparison between the three groups was performed, with no statistical difference found between groups 1 and 3 [11/67 (16.4%) vs 7/40 (17.5%)]. Rates of asthenia, loss of concentration, and insomnia in group 2 were significantly higher (65/67; 97.5%) when compared with those in groups 1 and 3 (P<0.001). In group 1, serum ferritin decreased from a mean pretreatment level of 800 ng/ ml to 320 ng/ml after treatment (Fig. 3) . In contrast, in group 2, we observed a slight reduction in mean ferritin level from a pretreatment value of 790 ng/ml to 580 ng/ml after treatment (Fig. 3) .
No patient in group 1 showed adverse effects of epoetin alpha administration. No severe psychiatric side effects, such as major depression or psychosis, were reported during antiviral treatment or follow-up. In 13 patients of 
MLR analyses
Significant predictors of SVR are presented in Table 2 . In our regression model, factors significantly associated with achieving SVR were RBV exposure (P<0.001) and epoetin alpha addition (P < 0.001).
Discussion
Combination treatment with peg-IFN and RBV represents the gold standard in the treatment of CH C. During HCV infection, factors associated with a favorable response to peg-INF and RBV therapy are viral genotypes 2 or 3, low levels of viremia before treatment, young age, absence of obesity and insulin resistance, and a low grade of fibrosis. In patients with CH, it is extremely important to ensure complete adherence to therapy with peg-IFN and RBV in order to achieve therapeutic success (greater percentage of SVR). Indeed, early interruption of therapy or reduction of peg-IFN or RBV dose because of side effects leads to a significant decrease in SVR [21, [41] [42] [43] .
After 12 weeks of therapy, in patients with an EVR, which means a reduction in HCV RNA of at least 2 log 10 in comparison with baseline, adherence to the "80/80/80 rule" is highly predictive of an SVR. This rule, which means taking 80% of the dose of peg-IFN and RBV for at least 80% of the duration of therapy, yields a greater SVR [41- 45] . Thus, exposure to an optimal treatment regimen, which consists of the full dose of drugs and prolonged treatment, is important in achieving successful treatment target, as it results from our logistic regression model for SVR (primary endpoint). This target was obtained by the addition of epoetin alpha, whereas the development of anemia leads to RBV dose reduction as standard of care (SOC). In fact, HCV-related genotype 1b CH patients who receive 80% of the full dose of peg-IFN and RBV for 48 weeks show a higher SVR than patients with the same virological features of hepatic disease who receive a reduced dose of drugs. This is because the maintenance of optimal drug levels allows the patient to achieve a strong and complete inhibition of viral replication [45] . During therapy with peg-IFN and RBV, alterations of the hematological profile and, in particular, evidence of neutropenia, thrombocytopenia, and anemia, are critical factors that play an important role in reduced dose and duration of therapy. Anemia caused by peg-IFN is additional to that induced by RBV [15] . Therefore, anemia represents a frequent side effect that may lead to reduced exposure time and dose of antiviral drugs, with consequent incomplete control of viral replication and clinical, biochemical, and histological progression of hepatic disease [18, 20, 22, 23, 46] .
The use of adjuvant agents (erythropoietin and granulocyte colony stimulating factor) to reduce the frequency of dose reductions because of hematological side effects has been proven to be effective, but there are few reports of what effect the use of these adjuvant therapies has upon SVR. Our research showed that patients in group 1, who were treated throughout with the initial dose of RBV along with epoetin alpha after anemia onset, showed a greater rate of SVR than patients in group 2, who were treated with a reduced dose of RBV without epoetin alpha after anemia onset. In particular, the rate of SVR in group 1 was 59.7% compared with 34.4% (P<0.01) achieved in group 2 (Table 3) . Group 1 SVR rate was similar to SVR rate in our control group (early responders who experienced no Hb reduction during the entire therapy and survey period) with no statistical difference.
Our results are in accordance with some recent studies [47] [48] [49] . Shiffman et al. observed a lower rate of relapse and a higher rate of SVR in patients treated with a higher starting dose of RBV (15.2 mg/kg/day) plus epoetin alpha compared with those treated with a lower dose of RBV (13.3 mg/kg/ day) with or without epoetin alpha [50] . Moreover, in a retrospective observational cohort study of predictors of SVR to peg-IFN and RBV in routine medical practice at Department of Veterans Affairs facilities, Backus et al. identified, by univariate and multivariate analyses the use of epoetin alpha as an independent predictor of SVR [51] . In the Cash et al. paper, the aim of the study was to assess the clinical impact on SVR of adjuvant therapies (erythropoietin and granulocyte colony stimulating factor) during combination therapy with peg-IFN and RBV for CH C; the authors have shown that in CH genotype 1 related patients, SVR can be improved with the use of erythropoietins [52] .
It may be assumed that there is no cost-benefit relationship for the use of epoetin alpha in patients with cirrhosis because of the high cost of epoetin alpha therapy, as with other hematological growth factors. However, some studies have used decision analysis to estimate the costeffectiveness of adjunctive therapy with erythropoietic growth factor (EGF) compared with that of standard care in the treatment of hepatitis C. The use of EGFs appears to be cost-effective in patients with anemia who are receiving combination therapy for HCV genotypes 1, 2, or 3. Compared with standard care, adjuvant therapy with EGF may increase the probability of achieving an SVR, increase unadjusted lifespan, and improve quality-adjusted lifespan at an acceptable cost [52] [53] [54] [55] . The results of previous studies [27, 28, 30, 37, 49, 50, 52, [56] [57] [58] and the study we present here have shown that the introduction of epoetin alpha therapy in patients treated with peg-IFN alpha-2A and RBV for CH related to genotype 1b HCV infection leads to an improved adherence to treatment and, consequently, to a significant improvement of SVR. Moreover, reduction in ferritinemia observed in group 1 in this study may have contributed to the better therapeutic response to peg-IFN and RBV treatment. The favorable trend in ferritinemia in group 1 may have been the consequence of decreased hepatic necroinflammation secondary to antiviral therapy, as well as the major movement of iron deposits toward the erythropoietic medulla secondary to epoetin alpha administration.
In conclusion, our data suggest that in patients with genotype 1b HCV-related CH who develop anemia during therapy with peg-IFN alpha-2A and RBV, the administration of epoetin alpha is justified because it ensures normal levels of Hb and increases SVR rate, assuring exposure to the optimal RBV dosage, thereby improving patient's adherence to treatment and thus their QOL. However, more data are necessary to clarify when epoetin alpha treatment should be started, treatment duration, optimal dosage, effect on end-of-treatment and SVR, and costs.
